{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-21-000152","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2021-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.234729+00:00","generated_at":"2026-06-30T03:43:24.621604+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Sesen Bio appoints two new directors with regulatory and clinical expertise","bullets":["Peter K Honig, MD (former Pfizer global regulatory head) and Michael A.S. Jewett, MD (urologic oncologist and Order of Canada) elected to Board.","Board size increased from 5 to 7 members; both appointed effective July 20, 2021.","Each new director received initial option to purchase 185,000 shares at $3.86 per share.","Company reiterates on track for FDA decision on Vicineum BLA by PDUFA date August 18, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-21-000152","json":"https://secwatch.observer/filing/0001485003-21-000152.json","markdown":"https://secwatch.observer/filing/0001485003-21-000152.md","text":"https://secwatch.observer/filing/0001485003-21-000152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500321000152/0001485003-21-000152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500321000152/sesn-20210720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T03:43:24.621604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12155b3d88","claim":"Michael A.S. Jewett, M.D. was elected as Director at Carisma Therapeutics Inc..","evidence_excerpt":"elected Peter K Honig, M.D. and Michael A.S. Jewett, M.D. to the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500321000152/0001485003-21-000152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f9f4d43565","claim":"Peter K Honig, M.D. was elected as Director at Carisma Therapeutics Inc..","evidence_excerpt":"elected Peter K Honig, M.D. and Michael A.S. Jewett, M.D. to the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500321000152/0001485003-21-000152-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}